Treatment of familial erythermalgia with the association of lidocaine and mexiletine;Traitement de l'erythermalgie familiale par l'association lidocaïne-mexilétine

Annales de Dermatologie et de Venereologie

Volumn 130, Issue 4, 2003, Pages 429-433

  Legroux Crespel, E ^a   Sassolas, B ^a   Guillet, G ^a   Kupfer, I ^a   Dupre, D ^a   Misery, L ^a  

^a BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LIDOCAINE; MEXILETINE; SODIUM CHANNEL; LOCAL ANESTHETIC AGENT; SODIUM CHANNEL BLOCKING AGENT;

ADOLESCENT; ADULT; ANALGESIA; ARTICLE; CASE REPORT; CHILDHOOD; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; DRUG TOLERABILITY; ERYTHROMELALGIA; FAMILIAL DISEASE; FEMALE; HEADACHE; HUMAN; MALE; QUALITY OF LIFE; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; WATER IMMERSION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANESTHETICS, LOCAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ERYTHROMELALGIA; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LIDOCAINE; MALE; MEXILETINE; SODIUM CHANNEL BLOCKERS; TREATMENT OUTCOME;

EID: 0037701447     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Cohen JS. Erythromelalgia: new theories and new therapies. J Am Acad Dermatol 2000;43:841-7.
2. Davis MD, O'Fallon WM, Rogers RS, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol 2000;136:330-6.
3. Lorette G, Machet L. Erythromélalgie. Ann Dermatol Venereol 1991;118:739-42.
4. Levesque H. Erythermalgies. Rev Prat 1998;48:1669-72.
5. Kuhnert SM, Phillips WJ, Davis MD. Lidocaine and mexiletine therapy for erythromelalgia. Arch Dermatol 1999;135:1447-9.
6. Lefaucheur JP. Dysfonction des canaux ioniques et neuropathies périphériques. Rev Neurol 2001;157:477-9.
7. Guillet MH, Le Noach E, Milochau P, Sassolas B, Guillet G. Erythermalgie familiale traitée par pizotifène. Ann Dermatol Venereol 1995;122:777-9.
8. Drenth JP, Finley WH, Breedveld GJ, Testers L, Michiels JJ, Guillet G et al. The primary erythermalgia-susceptibility gene is located on chromosome 2q31-32. Am J Hum Genet 2001;68:1277-82.
9. Uno H, Parker F. Autonomic innervation of the skin in primary erythermalgia. Arch Dermatol 1983;119:65-71.
10. Serratrice G, Godde JL and Schiano A. Traitement de l'érythermalgie avec des agents bêta-bloquants Nouv Presse Med 1977;6:3973.
11. Hodara M. Erythermalgie. J Mal Vasc 1988;13:159-61.
12. Bada JL. Treatment of erythromelalgia with propranolol. Lancet 1977;2:412.
13. Jelinek VM. A study in erythromelalgia. Australas Ann Med 1970;19: 139-44.
14. Pepper H. Primary erythermalgia. Report of a patient treated with methysergide maleate. JAMA 1968;203:1066-7.
15. H'Mila R, Samoud A, Souid M, Bourassine A, Ben Dridi MF. Erythermalgie: un acrosyndrome vasculaire rare. Arch Fr Pediatr 1991;48:555-7.
16. Moiin A, Yashar SS, Sanchez JE, Yashar B. Treatment of erythromelalgia with a serotonin/noradrenaline reuptake inhibitor. Br J Dermatol 2002;146:336-7.
17. Muhiddin KA, Gallen IW, Harries S, Pearce VR. The use of capsaicin cream in a case of erythromelalgia. Postgrad Med J 1994;70:841-3.
18. Drenth JP, Michiels JJ, Van Joost T. Substance P is not involved in primary and secondary erythermalgia. Acta Derm Venereol 1997;77:325-6.
19. Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci 1999;162:162-8.
20. Jarvis B, Coukell AJ. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs 1998;56:691-707.